Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study (BONE:STAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03916328
Recruitment Status : Recruiting
First Posted : April 16, 2019
Last Update Posted : January 18, 2020
Sponsor:
Information provided by (Responsible Party):
MU-JHU CARE

Brief Summary:
The primarily objective of this study is to assess the effect of switching from Tenofovir Disoproxil Fumurate (TDF) to TAF based ART on bone mass and turnover among women on DMPA for contraception. HIV virologically suppressed women on DMPA will be switched from their TDF based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®) in a randomized fashion. HIV infected women on TDF and non-hormonal contraception will be switched to Biktarvy®).

Condition or disease Intervention/treatment Phase
Bone Loss Drug: B/F/TAF Drug: TDF/3TC/EFV or DTG or NVP Other: DMPA Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumurate Switched to Tenofovir Alafenamide Fumarate Based Anti-Retroviral Therapy
Actual Study Start Date : December 3, 2019
Estimated Primary Completion Date : June 6, 2022
Estimated Study Completion Date : June 6, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: DMPA+ and TDF+
HIV-infected women on DMPA, and TDF containing ART.
Drug: TDF/3TC/EFV or DTG or NVP
A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.

Other: DMPA
Two thirds of the women will be on DMPA for contraception.
Other Name: Depo-provera

Experimental: DMPA+ and B/F/TAF+
HIV-infected women on DMPA, and B/F/TAF.
Drug: B/F/TAF
A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
Other Name: Biktarvy®)

Other: DMPA
Two thirds of the women will be on DMPA for contraception.
Other Name: Depo-provera

Experimental: DMPA- and B/F/TAF+
HIV-infected women on non hormonal contraception, and B/F/TAF.
Drug: B/F/TAF
A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
Other Name: Biktarvy®)




Primary Outcome Measures :
  1. Changes in bone mineral density [ Time Frame: 2 years ]
    We will assess percent change in BMD among DMPA users who switch to B/F/TAF compared to DMPA users remaining on TDF based ART

  2. Changes in trabeculae bone score (TBS) [ Time Frame: 2 years ]
    We will assess percent change in TBS among DMPA users who switch to B/F/TAF compared to DMPA users remaining on TDF based ART


Secondary Outcome Measures :
  1. Changes in bone biomarkers [ Time Frame: 2 years ]
    We will compare changes in bone turnover markers (CTX and P1NP) in B/F/TAF switchers with and without DMPA use



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   20 - 40 year old HIV-infected non pregnant women
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 20 through 40 years (inclusive) at screening, verified per site SOPs
  • Able and willing to provide written informed consent to be screened for and to take part in the study.
  • Able and willing to provide adequate locator information, as defined in site SOPs
  • Previously participated in the BONE: CARE study
  • Per participant report, plans to stay in the study catchment area in the next 24 months
  • Per participant report, willing to continue using similar contraceptive method as in the BONE: CARE study.

Exclusion Criteria:

  • Currently pregnant/ breastfeeding or was pregnant/ breastfeeding in the last 6 months prior to screening
  • Intentions to get pregnant in the next two years
  • History of active tuberculosis
  • Pathologic bone fracture not related to trauma (ever)
  • Has pre-existing condition known to affect bone metabolism (e.g. thyrotoxicosis, tuberculosis, diabetes mellitus, liver or renal disease)
  • Is taking the following medications known to interfere with bone metabolism (steroids, anti-convulsants, bisphosphonates, cancer drugs, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03916328


Contacts
Layout table for location contacts
Contact: Judith Mbanza, MA +256414541044 jmbanza@mujhu.org
Contact: Monica Nolan, M.B.B.S, MPH +256414541044 mnolan@mujhu.org

Locations
Layout table for location information
Uganda
MU-JHU Care Limited Recruiting
Kampala, Uganda, +256
Contact: Flavia Kiweewa Matovu, MBChB, MSc    +256414541044    fmatovu@mujhu.org   
Sponsors and Collaborators
MU-JHU CARE
Investigators
Layout table for investigator information
Principal Investigator: Flavia Kiweewa Matovu, MBChB, MSc MU-JHU CARE
Layout table for additonal information
Responsible Party: MU-JHU CARE
ClinicalTrials.gov Identifier: NCT03916328    
Other Study ID Numbers: CO-EU-380-5327
First Posted: April 16, 2019    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Medroxyprogesterone Acetate
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Male
Antineoplastic Agents, Hormonal
Antineoplastic Agents